CEO: Mr. Igor Lokot

Headquarters: US

Employees: 0

Homepage

Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders. The company offers Temodex, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. It is also developing Belopenem for the treatment of bacterial pneumonia. The company was founded in 2014 and is based in Uppsala, Sweden.

Innovator S&P 500 Ultra Buffer ETF - April New

SPDR® Portfolio S&P 500 High Dividend ETF

Norway Royal Salmon AS

Direct Line Insurance Group PLC